1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Global Haemophilia Therapeutics Market

  • April 2015
  • 105 pages
  • Frost & Sullivan
Report ID: 2861672

Summary

Table of Contents

Increased use of recombinant and prophylaxis therapies drives growth

This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.

Executive Summary—Key Findings

- 2014 turned out to be a flagship year in the development of recombinant factor replacement therapies for haemophilia.
o Biogen Idec got Food and Drug Administration (FDA) approval for two of its recombinant therapies, FVIII (Eloctate) and FIX (Alprolix), in 2014.
o Baxter’s Obizur, which is a novel recombinant porcine FVIII product used to treat patients with acquired haemophilia A (a rare bleeding disorder) and inhibitors, gained FDA approval in October 2014.
o Biological License Application (BLA) was submitted for four recombinant FVII therapies, including BAX 111 (Baxter), BAX 855 (Baxter), BAY 81-8973 (Bayer), and Nuwiq® (Octapharma), as well as one recombinant FIX therapy, namely rIX-FP (CSL Behring).
- Within the next two years (2015 and 2016), in the United States alone nearly seven new products are expected to enter the haemophilia recombinant therapeutics market.
o The new products are likely to offer significant efficacy and moderate convenience benefits to patients, providing considerable incentives to switch to newer therapies, especially in the rFIX segment.
- The global haemophilia therapeutics market was valued at $ billion in 2014 and is projected to grow at a CAGR of % to reach $ billion in 2019.
o Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of the disease, is expected to drive the growth of the global haemophilia therapeutics market.
o Recombinant therapies are likely to command a premium price and drive growth in the developed markets, while increased access to treatment and volumes per patient are likely to contribute to growth in the emerging markets.
o However, with several new recombinant products in the market, an increase in price pressure is anticipated, and negotiated discounts in emerging markets may drive down growth.
- Newer recombinant therapies are likely to gradually capture the share of the current leading participants, posing more of a long-term threat than a short-term one.
o Compelling convenience benefits are required for patients to switch therapies. None of the new rFVIII therapies has shown to extend half-life by more than %.
o The new market entrants such as Biogen Idec do not have well-established marketing/sales teams or good relationships with haematologists unlike the global big pharma companies.
o Moreover, global participants such as Bayer, Baxter, and Novo Nordisk have their own franchise of modified recombinant therapies in the pipeline to defend their market position.
- While the pipeline of recombinant replacement factors are maturing, other newer approaches are in the early phase of clinical development.
o Early proof-of-concept studies have shown that gene therapy can be a cost-effective alternative to treat haemophilia B patients.
o Companies such as Chatham Therapeutics and Amsterdam Molecular Therapeutics/uniQure are currently investigating new compounds in Phase I trials.
o Other novel therapeutics in early-stage pipeline include concizumab, a monoclonal antibody from Novo Nordisk, and ALN-AT3, an RNA interference therapeutic from Alnylam Pharmaceuticals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Summary Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US - Forecast

  • June 2017
    4 pages
  • Therapy  

    Therapy  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • June 2017
    4 pages
  • Therapy  

    Cancer  

  • United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • June 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Therapy Market

2 days ago

Diabetes Statistics

2 days ago

Related Market Segments :

Therapy
Blood Disease

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.